tetano
Editor, Senior Moderator
Mult Scler Relat Disord
. 2020 May 19;44:102199.
doi: 10.1016/j.msard.2020.102199. Online ahead of print.
Mild COVID-19 Infection Despite Chronic B Cell Depletion in a Patient With aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder
Marina A Creed[SUP] 1 [/SUP], Enrique Ballesteros[SUP] 2 [/SUP], L John Greenfield Jr[SUP] 3 [/SUP], Jaime Imitola[SUP] 4 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus SARS-CoV-2, which affects the lung and other organs. After an incubation period of 3-14 days, the infection presents with symptoms of variable severity, from mild flu-like disease to severe pneumonia and cytokine storm with increased mortality. Immunosuppressed patients may have higher risk of adverse outcomes; hence, there is an urgent need to evaluate the immune response and clinical outcomes of SARS-CoV-2 infection in these patients. Here, we report a 59-year-old woman with aquaporin-4-positive (AQPR4+) neuromyelitis Optica treated with rituximab who developed mild respiratory symptoms with COVID-19, despite B cell depletion at the time of infection.
Keywords: COVID-19; Multiple Sclerosis; Neuromyelitis Optica Spectrum Disorder (NMOSD); SARS-CoV-2; coronaviruses; pandemic.
. 2020 May 19;44:102199.
doi: 10.1016/j.msard.2020.102199. Online ahead of print.
Mild COVID-19 Infection Despite Chronic B Cell Depletion in a Patient With aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder
Marina A Creed[SUP] 1 [/SUP], Enrique Ballesteros[SUP] 2 [/SUP], L John Greenfield Jr[SUP] 3 [/SUP], Jaime Imitola[SUP] 4 [/SUP]
Affiliations
- PMID: 32554285
- DOI: 10.1016/j.msard.2020.102199
Abstract
Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus SARS-CoV-2, which affects the lung and other organs. After an incubation period of 3-14 days, the infection presents with symptoms of variable severity, from mild flu-like disease to severe pneumonia and cytokine storm with increased mortality. Immunosuppressed patients may have higher risk of adverse outcomes; hence, there is an urgent need to evaluate the immune response and clinical outcomes of SARS-CoV-2 infection in these patients. Here, we report a 59-year-old woman with aquaporin-4-positive (AQPR4+) neuromyelitis Optica treated with rituximab who developed mild respiratory symptoms with COVID-19, despite B cell depletion at the time of infection.
Keywords: COVID-19; Multiple Sclerosis; Neuromyelitis Optica Spectrum Disorder (NMOSD); SARS-CoV-2; coronaviruses; pandemic.